Concepts (283)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 31 | 2024 | 21163 | 1.860 |
Why?
|
Early Detection of Cancer | 13 | 2024 | 3236 | 1.180 |
Why?
|
Career Mobility | 4 | 2020 | 262 | 1.130 |
Why?
|
Faculty, Medical | 4 | 2017 | 1218 | 0.890 |
Why?
|
Spirituality | 6 | 2023 | 430 | 0.840 |
Why?
|
Mammography | 10 | 2024 | 2434 | 0.810 |
Why?
|
Community Health Centers | 4 | 2024 | 469 | 0.760 |
Why?
|
Pamphlets | 1 | 2020 | 71 | 0.680 |
Why?
|
Reproductive History | 3 | 2024 | 210 | 0.660 |
Why?
|
Health Occupations | 1 | 2020 | 225 | 0.640 |
Why?
|
Education, Distance | 1 | 2022 | 261 | 0.620 |
Why?
|
Biomedical Research | 3 | 2020 | 3464 | 0.600 |
Why?
|
Lung Neoplasms | 8 | 2024 | 13576 | 0.560 |
Why?
|
Cultural Diversity | 1 | 2020 | 373 | 0.550 |
Why?
|
Health Literacy | 1 | 2022 | 468 | 0.540 |
Why?
|
Awareness | 1 | 2019 | 653 | 0.470 |
Why?
|
Telomere | 1 | 2020 | 943 | 0.460 |
Why?
|
Adiposity | 2 | 2021 | 1895 | 0.440 |
Why?
|
Financing, Government | 1 | 2017 | 473 | 0.440 |
Why?
|
Breast | 5 | 2023 | 1975 | 0.430 |
Why?
|
Research Support as Topic | 1 | 2017 | 696 | 0.420 |
Why?
|
Patient Education as Topic | 2 | 2020 | 2337 | 0.410 |
Why?
|
Leukocytes | 1 | 2020 | 2030 | 0.400 |
Why?
|
Health Status Disparities | 4 | 2024 | 1882 | 0.400 |
Why?
|
Socioeconomic Factors | 6 | 2022 | 7861 | 0.400 |
Why?
|
Academic Medical Centers | 3 | 2017 | 2783 | 0.370 |
Why?
|
Female | 65 | 2024 | 397050 | 0.370 |
Why?
|
Head and Neck Neoplasms | 2 | 2023 | 2923 | 0.360 |
Why?
|
Obesity | 8 | 2023 | 13082 | 0.340 |
Why?
|
Smoking Cessation | 1 | 2021 | 2083 | 0.340 |
Why?
|
Middle Aged | 47 | 2024 | 223463 | 0.330 |
Why?
|
Communication | 4 | 2021 | 3912 | 0.330 |
Why?
|
Premenopause | 1 | 2013 | 1039 | 0.330 |
Why?
|
Body Mass Index | 8 | 2023 | 13050 | 0.310 |
Why?
|
Humans | 77 | 2024 | 768298 | 0.310 |
Why?
|
Fellowships and Scholarships | 1 | 2017 | 1133 | 0.310 |
Why?
|
Physicians | 2 | 2023 | 4614 | 0.300 |
Why?
|
Reproduction | 1 | 2013 | 646 | 0.300 |
Why?
|
Publishing | 1 | 2015 | 836 | 0.300 |
Why?
|
United States | 23 | 2024 | 73144 | 0.300 |
Why?
|
Self Report | 4 | 2022 | 3766 | 0.280 |
Why?
|
Religion | 4 | 2023 | 377 | 0.270 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3267 | 0.250 |
Why?
|
Gout | 2 | 2023 | 621 | 0.250 |
Why?
|
Mass Screening | 5 | 2024 | 5451 | 0.250 |
Why?
|
Adult | 37 | 2024 | 223622 | 0.240 |
Why?
|
Boston | 4 | 2023 | 9371 | 0.240 |
Why?
|
Overweight | 1 | 2016 | 2445 | 0.240 |
Why?
|
Social Class | 3 | 2022 | 2008 | 0.240 |
Why?
|
Telemedicine | 1 | 2022 | 3107 | 0.240 |
Why?
|
Aged | 32 | 2024 | 171544 | 0.240 |
Why?
|
Periodicals as Topic | 1 | 2016 | 1469 | 0.230 |
Why?
|
Hypertension | 5 | 2023 | 8615 | 0.230 |
Why?
|
Neoplasms | 5 | 2024 | 22389 | 0.230 |
Why?
|
Patient Participation | 1 | 2013 | 1448 | 0.220 |
Why?
|
Nurses | 1 | 2013 | 2494 | 0.210 |
Why?
|
Urban Population | 1 | 2010 | 2045 | 0.200 |
Why?
|
Medically Underserved Area | 1 | 2024 | 266 | 0.200 |
Why?
|
Ontario | 1 | 2022 | 403 | 0.190 |
Why?
|
Patient Selection | 2 | 2013 | 4265 | 0.190 |
Why?
|
Contraceptives, Oral | 3 | 2023 | 562 | 0.180 |
Why?
|
Residence Characteristics | 1 | 2010 | 2122 | 0.170 |
Why?
|
Receptor, erbB-2 | 2 | 2024 | 2588 | 0.170 |
Why?
|
Communicable Disease Control | 2 | 2023 | 857 | 0.170 |
Why?
|
Hyperuricemia | 1 | 2022 | 223 | 0.160 |
Why?
|
Colonoscopy | 2 | 2024 | 1412 | 0.160 |
Why?
|
Educational Status | 3 | 2021 | 2518 | 0.160 |
Why?
|
Masks | 1 | 2021 | 214 | 0.160 |
Why?
|
Prospective Studies | 12 | 2022 | 54921 | 0.150 |
Why?
|
Pandemics | 7 | 2022 | 8750 | 0.150 |
Why?
|
Exercise | 2 | 2012 | 5947 | 0.150 |
Why?
|
Adaptation, Psychological | 4 | 2023 | 2661 | 0.150 |
Why?
|
Neoplasm Staging | 6 | 2023 | 11254 | 0.150 |
Why?
|
Logistic Models | 5 | 2016 | 13323 | 0.150 |
Why?
|
Diphosphonates | 1 | 2022 | 635 | 0.150 |
Why?
|
Cross-Sectional Studies | 8 | 2023 | 26373 | 0.150 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.140 |
Why?
|
Pilot Projects | 3 | 2020 | 8730 | 0.140 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2021 | 705 | 0.140 |
Why?
|
Arteritis | 1 | 2019 | 158 | 0.140 |
Why?
|
Computers | 1 | 2020 | 592 | 0.140 |
Why?
|
Weight Loss | 4 | 2013 | 2715 | 0.140 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2023 | 2056 | 0.140 |
Why?
|
Receptor, Melatonin, MT1 | 1 | 2016 | 31 | 0.140 |
Why?
|
Comprehension | 1 | 2022 | 641 | 0.140 |
Why?
|
Smoking | 3 | 2024 | 9109 | 0.140 |
Why?
|
Proportional Hazards Models | 4 | 2016 | 12557 | 0.140 |
Why?
|
Health Services Needs and Demand | 2 | 2023 | 1406 | 0.130 |
Why?
|
Incidence | 6 | 2024 | 21544 | 0.130 |
Why?
|
Receptors, Estrogen | 2 | 2016 | 2247 | 0.130 |
Why?
|
Internet | 2 | 2022 | 3107 | 0.130 |
Why?
|
Parity | 2 | 2024 | 938 | 0.130 |
Why?
|
Cohort Studies | 6 | 2024 | 41791 | 0.130 |
Why?
|
Social Justice | 1 | 2020 | 486 | 0.130 |
Why?
|
Male | 27 | 2024 | 364870 | 0.130 |
Why?
|
Young Adult | 9 | 2022 | 60048 | 0.130 |
Why?
|
Amygdala | 2 | 2023 | 1382 | 0.120 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6856 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2021 | 4047 | 0.120 |
Why?
|
Social Stigma | 1 | 2021 | 785 | 0.120 |
Why?
|
Risk Factors | 13 | 2024 | 74954 | 0.120 |
Why?
|
Colorectal Neoplasms | 2 | 2024 | 6969 | 0.120 |
Why?
|
Quality of Life | 4 | 2023 | 13499 | 0.110 |
Why?
|
Schools, Medical | 2 | 2017 | 881 | 0.110 |
Why?
|
Stress, Psychological | 3 | 2023 | 4543 | 0.110 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2017 | 794 | 0.110 |
Why?
|
California | 2 | 2024 | 1443 | 0.110 |
Why?
|
Receptors, Progesterone | 2 | 2013 | 1145 | 0.110 |
Why?
|
Occult Blood | 2 | 2024 | 199 | 0.110 |
Why?
|
Organizational Culture | 1 | 2017 | 512 | 0.110 |
Why?
|
Awards and Prizes | 1 | 2017 | 365 | 0.100 |
Why?
|
Aspirin | 1 | 2024 | 3136 | 0.100 |
Why?
|
Research Personnel | 1 | 2017 | 590 | 0.100 |
Why?
|
Genome-Wide Association Study | 2 | 2022 | 12775 | 0.100 |
Why?
|
Efficiency | 1 | 2015 | 477 | 0.100 |
Why?
|
Age Factors | 4 | 2024 | 18472 | 0.100 |
Why?
|
Mentors | 1 | 2017 | 672 | 0.090 |
Why?
|
Age of Onset | 3 | 2016 | 3345 | 0.090 |
Why?
|
Melatonin | 1 | 2016 | 669 | 0.090 |
Why?
|
Physicians, Women | 1 | 2017 | 520 | 0.090 |
Why?
|
Menarche | 1 | 2013 | 538 | 0.090 |
Why?
|
Aged, 80 and over | 7 | 2024 | 59683 | 0.090 |
Why?
|
Demography | 1 | 2015 | 1642 | 0.090 |
Why?
|
Follow-Up Studies | 5 | 2016 | 39405 | 0.090 |
Why?
|
Perception | 1 | 2017 | 1206 | 0.090 |
Why?
|
Acidosis, Lactic | 1 | 1992 | 146 | 0.090 |
Why?
|
Body Height | 1 | 2016 | 1568 | 0.090 |
Why?
|
Patient Satisfaction | 2 | 2020 | 3485 | 0.080 |
Why?
|
Vaccination | 1 | 2022 | 3431 | 0.080 |
Why?
|
Health Promotion | 1 | 2021 | 2209 | 0.080 |
Why?
|
Physical Fitness | 1 | 2013 | 744 | 0.080 |
Why?
|
Family Characteristics | 1 | 2014 | 1003 | 0.080 |
Why?
|
Delivery of Health Care | 2 | 2024 | 5375 | 0.080 |
Why?
|
Women's Health | 2 | 2021 | 2078 | 0.080 |
Why?
|
Healthcare Disparities | 3 | 2024 | 3412 | 0.080 |
Why?
|
Nutrition Surveys | 3 | 2023 | 1736 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2022 | 2295 | 0.070 |
Why?
|
Internal Medicine | 1 | 2015 | 1057 | 0.070 |
Why?
|
Actigraphy | 1 | 2012 | 526 | 0.070 |
Why?
|
Urban Health | 1 | 2010 | 535 | 0.070 |
Why?
|
Time Factors | 3 | 2015 | 40267 | 0.070 |
Why?
|
Clinical Trials as Topic | 2 | 2016 | 8051 | 0.070 |
Why?
|
Cardiovascular Diseases | 2 | 2024 | 15652 | 0.070 |
Why?
|
Neurology | 1 | 2015 | 786 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2022 | 9433 | 0.070 |
Why?
|
Genes, BRCA1 | 2 | 2001 | 755 | 0.070 |
Why?
|
Self Care | 1 | 2012 | 797 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3381 | 0.070 |
Why?
|
Vulnerable Populations | 1 | 2012 | 718 | 0.070 |
Why?
|
Heart Diseases | 1 | 2019 | 2819 | 0.070 |
Why?
|
Behavior Therapy | 1 | 2012 | 885 | 0.070 |
Why?
|
Genetic Testing | 1 | 1999 | 3587 | 0.060 |
Why?
|
Sex Factors | 2 | 2017 | 10656 | 0.060 |
Why?
|
Health Behavior | 2 | 2021 | 2647 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 2 | 2016 | 3230 | 0.060 |
Why?
|
Odds Ratio | 2 | 2016 | 9681 | 0.060 |
Why?
|
Anesthesiology | 1 | 2015 | 1137 | 0.060 |
Why?
|
Multicenter Studies as Topic | 1 | 2010 | 1727 | 0.060 |
Why?
|
Self Concept | 1 | 2011 | 1047 | 0.060 |
Why?
|
South Dakota | 1 | 2024 | 32 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2022 | 16027 | 0.060 |
Why?
|
Neoadjuvant Therapy | 1 | 2016 | 2909 | 0.060 |
Why?
|
Cause of Death | 1 | 2015 | 3728 | 0.060 |
Why?
|
Primary Health Care | 2 | 2012 | 4748 | 0.060 |
Why?
|
Program Evaluation | 1 | 2013 | 2505 | 0.060 |
Why?
|
Risk Assessment | 3 | 2023 | 24316 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2015 | 12092 | 0.060 |
Why?
|
General Surgery | 1 | 2015 | 1712 | 0.060 |
Why?
|
Survival Analysis | 1 | 2016 | 10117 | 0.050 |
Why?
|
Lung | 1 | 2022 | 10087 | 0.050 |
Why?
|
Energy Intake | 1 | 2011 | 2145 | 0.050 |
Why?
|
Massachusetts | 3 | 2024 | 8902 | 0.050 |
Why?
|
Psychiatry | 1 | 2015 | 1715 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2024 | 13696 | 0.050 |
Why?
|
Phenotype | 1 | 2021 | 16716 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3118 | 0.050 |
Why?
|
Vitamin D | 1 | 2016 | 3311 | 0.050 |
Why?
|
Decision Making | 1 | 2016 | 3953 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.050 |
Why?
|
Stroke | 1 | 2024 | 9742 | 0.050 |
Why?
|
Child | 3 | 2020 | 80894 | 0.050 |
Why?
|
Attitude to Health | 1 | 2011 | 2025 | 0.050 |
Why?
|
Adolescent | 3 | 2020 | 89182 | 0.050 |
Why?
|
Pregnancy | 3 | 2024 | 30198 | 0.050 |
Why?
|
Social Marketing | 1 | 2021 | 52 | 0.050 |
Why?
|
Radiology | 1 | 2015 | 2117 | 0.050 |
Why?
|
Risk | 1 | 2013 | 9635 | 0.050 |
Why?
|
Reminder Systems | 1 | 2024 | 387 | 0.050 |
Why?
|
Poverty | 1 | 2013 | 2721 | 0.050 |
Why?
|
Australia | 1 | 2024 | 1265 | 0.050 |
Why?
|
Ifosfamide | 2 | 1992 | 234 | 0.040 |
Why?
|
Advisory Committees | 1 | 2024 | 797 | 0.040 |
Why?
|
Treatment Outcome | 3 | 2016 | 65365 | 0.040 |
Why?
|
Anthracyclines | 1 | 2022 | 286 | 0.040 |
Why?
|
Pediatrics | 1 | 2015 | 3624 | 0.040 |
Why?
|
Eligibility Determination | 1 | 2023 | 421 | 0.040 |
Why?
|
Prognosis | 3 | 2023 | 30020 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2022 | 11220 | 0.040 |
Why?
|
Etoposide | 2 | 1992 | 639 | 0.040 |
Why?
|
Medicaid | 1 | 2012 | 2842 | 0.040 |
Why?
|
Genes, BRCA2 | 1 | 2001 | 592 | 0.040 |
Why?
|
Pituitary-Adrenal System | 1 | 2021 | 557 | 0.040 |
Why?
|
Cultural Competency | 1 | 2021 | 303 | 0.040 |
Why?
|
Canada | 2 | 2020 | 2139 | 0.040 |
Why?
|
Public Health | 2 | 2021 | 2681 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2001 | 18047 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2021 | 12239 | 0.040 |
Why?
|
Survival Rate | 2 | 2010 | 12870 | 0.030 |
Why?
|
Uric Acid | 1 | 2023 | 806 | 0.030 |
Why?
|
Retinoid X Receptors | 1 | 2016 | 91 | 0.030 |
Why?
|
Radioimmunoassay | 1 | 2016 | 862 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20766 | 0.030 |
Why?
|
Disease Transmission, Infectious | 1 | 2021 | 562 | 0.030 |
Why?
|
Case-Control Studies | 3 | 2019 | 22292 | 0.030 |
Why?
|
Prevalence | 2 | 2023 | 15868 | 0.030 |
Why?
|
Health Communication | 1 | 2018 | 216 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 749 | 0.030 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 1992 | 5422 | 0.030 |
Why?
|
Cisplatin | 2 | 1992 | 1661 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2016 | 551 | 0.030 |
Why?
|
Creatine | 1 | 2016 | 427 | 0.030 |
Why?
|
Minority Groups | 1 | 2022 | 1215 | 0.030 |
Why?
|
Research Design | 1 | 2010 | 6209 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 1992 | 6404 | 0.030 |
Why?
|
Receptors, Calcitriol | 1 | 2016 | 361 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2012 | 20224 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2023 | 2734 | 0.030 |
Why?
|
Social Perception | 1 | 2017 | 433 | 0.030 |
Why?
|
Qualitative Research | 1 | 2024 | 3131 | 0.030 |
Why?
|
Job Satisfaction | 1 | 2017 | 549 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2001 | 1885 | 0.030 |
Why?
|
Prejudice | 1 | 2017 | 574 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 1992 | 11854 | 0.030 |
Why?
|
Prostate-Specific Antigen | 1 | 2022 | 2487 | 0.030 |
Why?
|
Medical Oncology | 1 | 2024 | 2348 | 0.020 |
Why?
|
Therapy, Computer-Assisted | 1 | 2014 | 265 | 0.020 |
Why?
|
Menopause | 1 | 2019 | 1653 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2019 | 14783 | 0.020 |
Why?
|
Body Weight | 1 | 2021 | 4630 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2023 | 3627 | 0.020 |
Why?
|
Paraneoplastic Syndromes | 1 | 1992 | 155 | 0.020 |
Why?
|
Hematopoiesis | 1 | 2019 | 2058 | 0.020 |
Why?
|
Drug Evaluation | 1 | 1990 | 642 | 0.020 |
Why?
|
Telephone | 1 | 2012 | 630 | 0.020 |
Why?
|
Neutropenia | 2 | 1992 | 893 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2016 | 3794 | 0.020 |
Why?
|
Mental Health | 1 | 2022 | 3276 | 0.020 |
Why?
|
Leadership | 1 | 2017 | 1395 | 0.020 |
Why?
|
Thinness | 1 | 2011 | 483 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 1999 | 3609 | 0.020 |
Why?
|
Postmenopause | 1 | 2016 | 2518 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2013 | 1669 | 0.020 |
Why?
|
DNA Methylation | 1 | 2021 | 4419 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6670 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 712 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2014 | 1440 | 0.020 |
Why?
|
Medicare | 1 | 2023 | 6881 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2001 | 4908 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2010 | 1445 | 0.010 |
Why?
|
Counseling | 1 | 2012 | 1553 | 0.010 |
Why?
|
Reference Values | 1 | 2011 | 4941 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2024 | 11515 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2014 | 5311 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11117 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2023 | 81768 | 0.010 |
Why?
|
Transcription Factors | 1 | 1999 | 12166 | 0.010 |
Why?
|
District of Columbia | 1 | 1999 | 159 | 0.010 |
Why?
|
Founder Effect | 1 | 1999 | 185 | 0.010 |
Why?
|
Algorithms | 1 | 1999 | 14154 | 0.010 |
Why?
|
Jews | 1 | 1999 | 358 | 0.010 |
Why?
|
Blood Pressure | 1 | 2012 | 8541 | 0.010 |
Why?
|
Mutation | 1 | 1999 | 30230 | 0.010 |
Why?
|
Family Health | 1 | 1999 | 1255 | 0.010 |
Why?
|
BRCA2 Protein | 1 | 1999 | 802 | 0.010 |
Why?
|
Diet | 1 | 2011 | 8097 | 0.010 |
Why?
|
Heterozygote | 1 | 1999 | 2792 | 0.010 |
Why?
|
Gene Frequency | 1 | 1999 | 3615 | 0.010 |
Why?
|
Agranulocytosis | 1 | 1992 | 98 | 0.010 |
Why?
|
Alleles | 1 | 2001 | 6892 | 0.010 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 1992 | 640 | 0.010 |
Why?
|
Vomiting | 1 | 1992 | 655 | 0.000 |
Why?
|
Remission Induction | 1 | 1992 | 2407 | 0.000 |
Why?
|
Bone Marrow | 1 | 1992 | 2929 | 0.000 |
Why?
|
Concepts
(283)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(95)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_